logo
Plus   Neg
Share
Email

Pentair Backs FY19 Earnings Guidance - Quick Facts

While reporting financial results for the third quarter on Wednesday, Pentair plc (PNR) maintained its earnings and adjusted earnings guidance for the full-year 2019, while trimming sales growth guidance. The company also initiated fourth-quarter outlook.

For fiscal 2019, the company continues to project earnings of about $2.09 per share and adjusted earnings of about $2.35 per share. The company now expects sales to be about flat on a reported basis and down about 1 percent on a core basis from last year.

Previously, the company expected annual sales to be flat to up about 1 on a reported basis and about flat to down 1 percent on a core basis

On average, 17 analysts polled by Thomson Reuters expect the company to report earnings of $2.33 per share on sales growth of 0.4 percent to $2.98 billion for the year. Analysts' estimates typically exclude special items.

For the fourth quarter, the company projects earnings in a range of about $0.60 to $0.62 per share and on an adjusted basis in a range of about $0.64 - $0.66 per share on sales growth of about 2 percent on a reported basis and about flat on a core basis from last year.

The Street is looking for earnings of $0.66 per share on sales growth of 3.7 percent to $767.91 million for the quarter.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Amity Packing Company Inc. is recalling around 2,020 pounds of raw ground beef products for possible plastic presence, the U.S. Department of Agriculture's Food Safety and Inspection Service stated. The agency said the products may be contaminated with extraneous materials, specifically clear, thin pliable plastic. The recall was initiated after Pre Brands LLC received two consumer complaints. Golden Pearl Trading Corp. is recalling certain ready-to-eat or RTE imported Siluriformes products that were produced without benefit of import inspection, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS announced. The recall involves around 12,054 pounds of Siluriformes products that were not presented for import re-inspection into the United States. The U.S. Food and Drug Administration has granted accelerated approval to Tazverik for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Epithelioid sarcoma is a rare sub-type of soft...
Follow RTT
>